AtriCure Company Profile (NASDAQ:ATRC)

About AtriCure (NASDAQ:ATRC)

AtriCure logoAtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart's left atrial appendage (LAA).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution - NEC
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:ATRC
  • CUSIP: 04963C20
  • Web:
  • Market Cap: $785.52 million
  • Outstanding Shares: 33,946,000
Average Prices:
  • 50 Day Moving Avg: $23.44
  • 200 Day Moving Avg: $20.02
  • 52 Week Range: $13.45 - $25.11
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -36.60
  • P/E Growth: -1.23
Sales & Book Value:
  • Annual Revenue: $160.44 million
  • Price / Sales: 4.80
  • Book Value: $4.74 per share
  • Price / Book: 4.79
  • EBIDTA: ($21,000,000.00)
  • Net Margins: -21.07%
  • Return on Equity: -19.89%
  • Return on Assets: -12.25%
  • Debt-to-Equity Ratio: 0.22%
  • Current Ratio: 2.79%
  • Quick Ratio: 2.12%
  • Average Volume: 171,756 shs.
  • Beta: 0.79
  • Short Ratio: 14.02
Frequently Asked Questions for AtriCure (NASDAQ:ATRC)

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) released its quarterly earnings data on Thursday, May, 4th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.01. The company had revenue of $41.30 million for the quarter, compared to analysts' expectations of $40.25 million. AtriCure had a negative return on equity of 19.89% and a negative net margin of 21.07%. AtriCure's revenue was up 15.0% compared to the same quarter last year. During the same period last year, the firm posted ($0.31) earnings per share. View AtriCure's Earnings History.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure updated its FY17 earnings guidance on Thursday, July, 27th. The company provided EPS guidance of $(1.04)-(0.94) for the period, compared to the Thomson Reuters consensus earnings per share estimate of ($0.96). The company issued revenue guidance of $177-178 million, compared to the consensus revenue estimate of $175.85 million.

Where is AtriCure's stock going? Where will AtriCure's stock price be in 2017?

8 equities research analysts have issued 12 month target prices for AtriCure's stock. Their predictions range from $19.00 to $26.00. On average, they expect AtriCure's share price to reach $23.25 in the next year. View Analyst Ratings for AtriCure.

What are analysts saying about AtriCure stock?

Here are some recent quotes from research analysts about AtriCure stock:

  • 1. According to Zacks Investment Research, "AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart. " (5/10/2017)
  • 2. Needham & Company LLC analysts commented, "ATRC’s 1Q17 revenue, EBITDA, and EPS beat consensus and management maintained its 2017 guidance. Worldwide Open-Heart Ablation growth improved to 10% from 7% in 4Q16 and US Open-Heart Ablation growth increased to 12% from 1% in 4Q16. We think that the improved Open-Heart growth should help to reduce concerns that this business is in a permanent slowdown and we expect the new guidelines for ablation in concomitant open-heart procedures to drive stronger growth over time. ATRC shares remain at a large discount to peers (2017E EV/ sales of 4.0x vs. small/mid-cap growth peers at a median of 5.8x) and we reiterate our Buy rating." (5/5/2017)

Who are some of AtriCure's key competitors?

Who are AtriCure's key executives?

AtriCure's management team includes the folowing people:

  • Richard M. Johnston, Independent Chairman of the Board
  • Michael H. Carrel, President, Chief Executive Officer, Director
  • M. Andrew Wade CPA, Chief Financial Officer, Senior Vice President
  • Douglas J. Seith, Chief Operating Officer
  • Justin J. Noznesky, Senior Vice President, Marketing and Business Development
  • Andrew L. Lux Ph.D., Senior Vice President -Operations and Quality
  • Mark A. Collar, Independent Director
  • Scott William Drake, Independent Director
  • Regina E. Groves, Independent Director
  • Michael D. Hooven, Independent Director

Who owns AtriCure stock?

AtriCure's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (2.63%), Bollard Group LLC (0.59%), Perkins Capital Management Inc. (0.40%), Lockheed Martin Investment Management Co. (0.11%), Rockefeller Financial Services Inc. (0.03%) and Bank of Montreal Can (0.03%). Company insiders that own AtriCure stock include Andrew L Lux, Douglas J Seith and Elizabeth D Krell. View Institutional Ownership Trends for AtriCure.

Who sold AtriCure stock? Who is selling AtriCure stock?

AtriCure's stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Lockheed Martin Investment Management Co. and Perkins Capital Management Inc.. Company insiders that have sold AtriCure stock in the last year include Andrew L Lux and Elizabeth D Krell. View Insider Buying and Selling for AtriCure.

Who bought AtriCure stock? Who is buying AtriCure stock?

AtriCure's stock was acquired by a variety of institutional investors in the last quarter, including US Bancorp DE. View Insider Buying and Selling for AtriCure.

How do I buy AtriCure stock?

Shares of AtriCure can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AtriCure's stock price today?

One share of AtriCure stock can currently be purchased for approximately $22.69.

MarketBeat Community Rating for AtriCure (NASDAQ ATRC)
Community Ranking:  3.7 out of 5 (  )
Outperform Votes:  224 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  302
MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for AtriCure (NASDAQ:ATRC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $23.25 (2.47% upside)

Analysts' Ratings History for AtriCure (NASDAQ:ATRC)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/16/2017Leerink SwannReiterated RatingOutperform$26.00LowView Rating Details
5/30/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Overweight$26.00LowView Rating Details
5/5/2017Needham & Company LLCReiterated RatingBuy$23.00 -> $25.00HighView Rating Details
4/17/2017Canaccord GenuityReiterated RatingBuy$22.00LowView Rating Details
3/20/2017Northland SecuritiesReiterated RatingBuy$24.00LowView Rating Details
3/6/2017BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
8/6/2016JMP SecuritiesSet Price TargetBuy$23.00N/AView Rating Details
8/5/2016Stifel NicolausLower Price TargetBuy$26.00 -> $21.00N/AView Rating Details
7/28/2015Dougherty & CoBoost Price TargetBuy$25.00 -> $30.00N/AView Rating Details
(Data available from 7/28/2015 forward)


Earnings History for AtriCure (NASDAQ:ATRC)
Earnings by Quarter for AtriCure (NASDAQ:ATRC)
Earnings History by Quarter for AtriCure (NASDAQ ATRC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.33)($0.32)$40.25 million$41.30 millionViewListenView Earnings Details
2/28/2017Q4 2016($0.32)($0.27)$41.17 million$41.20 millionViewListenView Earnings Details
10/27/2016Q316($0.28)($0.21)$10.75 million$38.34 millionViewListenView Earnings Details
8/4/2016Q216($0.30)($0.26)$39.84 million$39.70 millionViewListenView Earnings Details
4/28/2016Q116($0.32)($0.31)$36.08 million$35.90 millionViewListenView Earnings Details
2/23/2016Q415($0.36)($0.36)$35.90 million$35.90 millionViewListenView Earnings Details
10/27/2015Q315($0.22)($0.22)$31.32 million$31.40 millionViewListenView Earnings Details
7/28/2015Q215($0.21)($0.18)$30.51 million$32.58 millionViewListenView Earnings Details
4/29/2015Q115($0.21)($0.19)$28.65 million$29.90 millionViewListenView Earnings Details
2/23/2015Q414($0.20)($0.20)$28.40 million$29.40 millionViewListenView Earnings Details
10/30/2014Q314($0.17)($0.02)$25.60 million$26.70 millionViewListenView Earnings Details
7/24/2014Q214($0.19)($0.10)$25.03 million$26.51 millionViewListenView Earnings Details
4/24/2014Q114($0.22)($0.31)$23.36 million$24.80 millionViewListenView Earnings Details
2/27/2014Q413($0.14)($0.24)$21.16 million$21.90 millionViewListenView Earnings Details
10/29/2013Q313($0.15)($0.13)$18.30 million$20.10 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.10)($0.09)$19.42 million$20.40 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.09)($0.10)$18.63 million$19.43 millionViewListenView Earnings Details
2/28/2013Q4 2012($0.09)($0.12)$18.46 million$18.40 millionViewListenView Earnings Details
11/1/2012Q312($0.11)($0.16)$17.29 million$16.10 millionViewN/AView Earnings Details
8/2/2012($0.07)($0.08)ViewN/AView Earnings Details
5/2/2012($0.13)($0.10)ViewN/AView Earnings Details
11/1/2011($0.07)($0.07)ViewN/AView Earnings Details
8/2/2011($0.01)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for AtriCure (NASDAQ:ATRC)
2017 EPS Consensus Estimate: ($1.09)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.37)($0.37)($0.37)
Q2 20171($0.29)($0.29)($0.29)
Q3 20171($0.23)($0.23)($0.23)
Q4 20171($0.20)($0.20)($0.20)
(Data provided by Zacks Investment Research)


Dividend History for AtriCure (NASDAQ:ATRC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for AtriCure (NASDAQ:ATRC)
Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 86.46%
Insider Trades by Quarter for AtriCure (NASDAQ:ATRC)
Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)
Insider Trades by Quarter for AtriCure (NASDAQ:ATRC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/17/2017Elizabeth D KrellDirectorSell10,000$21.44$214,400.00View SEC Filing  
3/17/2017Andrew L LuxSVPSell20,000$18.85$377,000.00View SEC Filing  
11/15/2016Elizabeth D KrellDirectorSell10,000$19.73$197,300.00View SEC Filing  
9/13/2016Elizabeth D KrellDirectorSell6,000$15.93$95,580.00View SEC Filing  
8/17/2016Elizabeth D KrellDirectorSell5,000$15.20$76,000.00View SEC Filing  
3/8/2016Elizabeth D KrellDirectorSell10,000$16.91$169,100.00View SEC Filing  
12/3/2015Douglas J. SeithCOOSell5,000$21.55$107,750.00View SEC Filing  
12/2/2015Elizabeth D. KrellDirectorSell10,000$21.88$218,800.00View SEC Filing  
11/11/2015Elizabeth D. KrellDirectorSell10,000$20.68$206,800.00View SEC Filing  
4/1/2015Michael D HoovenDirectorSell142,268$20.81$2,960,597.08View SEC Filing  
3/31/2015Michael D HoovenDirectorSell20,000$20.51$410,200.00View SEC Filing  
3/30/2015Michael D HoovenDirectorSell85,000$21.01$1,785,850.00View SEC Filing  
3/13/2015Karen P RobardsDirectorSell3,150$19.53$61,519.50View SEC Filing  
3/5/2015Douglas J SeithCOOSell36,688$17.51$642,406.88View SEC Filing  
3/2/2015Elizabeth D KrellDirectorSell10,000$17.63$176,300.00View SEC Filing  
5/6/2014Douglas SeithSVPBuy1,000$15.04$15,040.00View SEC Filing  
9/13/2013Richard JohnstonInsiderSell77,610$10.00$776,100.00View SEC Filing  
8/12/2013Douglas SeithSVPBuy10,000$9.58$95,800.00View SEC Filing  
8/5/2013Richard JohnstonInsiderSell20,047$10.00$200,470.00View SEC Filing  
7/11/2013Richard M JohnstonInsiderSell2,343$10.00$23,430.00View SEC Filing  
6/19/2013Richard M JohnstonInsiderSell29,348$8.96$262,958.08View SEC Filing  
6/18/2013Richard M JohnstonInsiderSell39,682$9.18$364,280.76View SEC Filing  
6/14/2013Richard M JohnstonInsiderSell95,598$8.97$857,514.06View SEC Filing  
6/12/2013Richard M JohnstonInsiderSell35,372$9.01$318,701.72View SEC Filing  
3/6/2013James L LuckyVPSell50,065$8.14$407,529.10View SEC Filing  
9/14/2012Mark R LanningDirectorBuy11,006$7.64$84,085.84View SEC Filing  
9/13/2012Michael D HoovenDirectorBuy1,110$7.37$8,180.70View SEC Filing  
9/12/2012Michael D HoovenDirectorBuy1,150$7.10$8,165.00View SEC Filing  
9/11/2012Michael D HoovenDirectorBuy1,145$7.18$8,221.10View SEC Filing  
9/10/2012Michael D HoovenDirectorBuy1,215$7.15$8,687.25View SEC Filing  
9/7/2012Michael D HoovenDirectorBuy1,215$6.88$8,359.20View SEC Filing  
8/23/2012Karen P RobardsDirectorBuy1,000$6.70$6,700.00View SEC Filing  
8/16/2012Karen P RobardsDirectorBuy1,000$6.98$6,980.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for AtriCure (NASDAQ:ATRC)
Latest Headlines for AtriCure (NASDAQ:ATRC)
DateHeadline logoAtriCure, Inc. (ATRC) Updates FY17 Earnings Guidance - July 27 at 11:34 PM logoAtriCure Reports Second Quarter 2017 Financial Results - July 27 at 9:02 PM logoAtriCure reports 2Q loss - July 27 at 9:02 PM logoInvestor Network: AtriCure, Inc. to Host Earnings Call - July 27 at 3:54 PM logo$44.23 Million in Sales Expected for AtriCure, Inc. (ATRC) This Quarter - July 27 at 11:39 AM logo-$0.25 EPS Expected for AtriCure, Inc. (ATRC) This Quarter - July 25 at 4:25 PM logoAtriCure, Inc. (ATRC) Given Consensus Recommendation of "Buy" by Brokerages - July 25 at 11:11 AM logoDayton-area health care firm adds to C-suite - July 20 at 5:40 PM logoAtriCure to Present at the Canaccord Genuity 37th Annual Growth Conference - July 20 at 5:39 PM logoAtriCure, Inc. (NASDAQ:ATRC) Set to Announce Earnings on Thursday - July 20 at 7:40 AM logoAtriCure (ATRC) to Hire Salvatore Privitera as New CTO - July 19 at 3:49 AM logoAtriCure Announces Hiring of Chief Technology Officer - July 18 at 5:44 PM logoETFs with exposure to AtriCure, Inc. : July 13, 2017 - July 13 at 4:59 PM logoAtriCure to Announce Second Quarter 2017 Financial Results - July 6 at 5:29 PM logo Brokerages Anticipate AtriCure, Inc. (ATRC) Will Post Quarterly Sales of $44.23 Million - July 1 at 9:00 AM logoAtriCure, Inc. (ATRC) Given Average Recommendation of "Buy" by Analysts - June 30 at 12:32 PM logoZacks: Brokerages Anticipate AtriCure, Inc. (ATRC) to Announce -$0.25 Earnings Per Share - June 29 at 12:48 PM logoAtriCure, Inc. (ATRC) Receives Outperform Rating from Leerink Swann - June 16 at 12:34 PM logoAtriCure, Inc. (ATRC) Raised to Hold at ValuEngine - June 12 at 11:36 PM logo Analysts Anticipate AtriCure Inc. (ATRC) Will Announce Quarterly Sales of $44.23 Million - June 7 at 11:24 AM logoReviewing AtriCure (ATRC) and Integra Lifesciences Holdings Corp (IART) - June 5 at 10:14 PM logoHead to Head Comparison: Invuity (IVTY) and AtriCure (ATRC) - June 5 at 8:46 PM logoAtriCure Inc. (ATRC) Expected to Post Earnings of -$0.25 Per Share - June 5 at 10:52 AM logoAtriCure Inc. (ATRC) Given Average Rating of "Buy" by Brokerages - June 5 at 9:15 AM logoPiper Jaffray Assumes AtriCure Inc. (ATRC) to Overweight - May 30 at 12:35 PM logoPiper Jaffray Companies Initiates Coverage on AtriCure Inc. (ATRC) - May 30 at 10:42 AM logoAtriCure to Present at the JMP Securities Life Science Conference - May 18 at 12:03 PM logoElizabeth D. Krell Sells 10,000 Shares of AtriCure Inc. (ATRC) Stock - May 17 at 7:47 PM logoAtriCure Inc. (ATRC) Upgraded by TheStreet to C- - May 17 at 6:32 PM logoETFs with exposure to AtriCure, Inc. : May 12, 2017 - May 12 at 4:16 PM logoAtriCure, Inc. :ATRC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 - May 10 at 8:53 PM logoAtriCure Inc. (ATRC) Lowered to "Hold" at Zacks Investment Research - May 10 at 7:36 PM logoAtriCure Inc. (ATRC) Upgraded at Zacks Investment Research - May 9 at 10:28 PM logo Brokerages Anticipate AtriCure Inc. (ATRC) Will Announce Earnings of -$0.24 Per Share - May 9 at 8:28 PM logoAtriCure Inc. (ATRC) Given Average Rating of "Buy" by Analysts - May 9 at 9:25 AM logoNeedham & Company LLC Reaffirms "Buy" Rating for AtriCure Inc. (ATRC) - May 6 at 2:04 PM logoAtriCure Inc. (ATRC) Posts Earnings Results, Beats Expectations By $0.01 EPS - May 5 at 3:58 PM logoHere's Why ArtiCure, Inc. Is Up Double-Digits Today - May 5 at 3:44 PM logoEdited Transcript of ATRC earnings conference call or presentation 4-May-17 8:30pm GMT - May 5 at 3:44 PM logoAtriCure Reports First Quarter 2017 Financial Results - May 4 at 8:48 PM logoAtriCure reports 1Q loss - May 4 at 8:48 PM logoAtriCure (ATRC) Receives Daily News Sentiment Rating of 0.31 - May 2 at 12:20 PM logoAtriCure Inc. (ATRC) Scheduled to Post Earnings on Thursday - May 2 at 9:58 AM logoThoughts On Consonance Capital's Positions - Part 2 - April 30 at 2:19 AM logoAtriCure (ATRC) Receives Media Impact Rating of 0.16 - April 29 at 9:58 AM logoAtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide - April 25 at 11:22 AM logoAtriCure (ATRC) Receiving Somewhat Favorable Press Coverage, Analysis Finds - April 24 at 6:00 PM logoAtriCure (ATRC) Earns Media Sentiment Rating of 0.06 - April 20 at 3:25 PM logoAtriCure Inc. (ATRC) Expected to Announce Quarterly Sales of $40.34 Million - April 20 at 10:01 AM logo Brokerages Anticipate AtriCure Inc. (ATRC) Will Post Earnings of -$0.33 Per Share - April 19 at 12:15 AM



AtriCure (ATRC) Chart for Friday, July, 28, 2017

This page was last updated on 7/28/2017 by Staff